Piramal Trims Research To Build Companions Of Neuraceq
This article was originally published in PharmAsia News
Executive Summary
Piramal Lifesciences has cut its research focus, eliminating drugs in the early stage development. Instead, the company will build on products that can be “companion products” to its newly launched flagship brand Neuraceq, used to detect symptoms associated with Alzheimer’s disease.
You may also be interested in...
India’s Piramal Ropes In Big Pharma Heavyhitters To Support Late-Stage R&D
MUMBAI - A progressively maturing pipeline of innovative compounds has led Piramal Healthcare Ltd. to begin adding leadership positions to its core research team. Piramal is believed to be drawing senior-level executives from established global companies in functions like drug discovery, development, international regulatory affairs and marketing strategies to ramp up expertise in late-stage processes
Ajay Piramal Aims At Lead Ranks In CRAMS, OTC And Critical Care Business; Reveals Details On Abbott Deal
MUMBAI - Giving up one flourishing unit seems to have created larger business opportunities for a few others that form part of Indian industrialist Ajay Piramal's enterprise Piramal Healthcare
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.